{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T01:23:17Z","timestamp":1781659397118,"version":"3.54.5"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,4,18]],"date-time":"2020-04-18T00:00:00Z","timestamp":1587168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,4,18]],"date-time":"2020-04-18T00:00:00Z","timestamp":1587168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Oulu University"},{"DOI":"10.13039\/100017400","name":"Finnish Cancer Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017400","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Introduction<\/jats:title>\n<jats:p>Immune checkpoint inhibitors (ICIs) are approved in multiple indications for cancer care. Most of the clinical trials have not questioned shorter than until disease progression approaches. In this study, we present results from a cohort of multiple advanced cancers treated with restricted anti-PD-(L)1 therapy.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>All patients with advanced cancers treated with anti-PD-(L)1 therapy outside clinical trials at Oulu University Hospital 2014\u201319 were retrospectively identified from pharmacy records. Clinical variables, treatment history and survival were collected.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>106 patients with median age of 66\u00a0years with lung cancer (<jats:italic>n<\/jats:italic>\u2009=\u200945, 42.5%), melanoma (<jats:italic>n<\/jats:italic>\u2009=\u200930, 28.3%), renal and bladder cancers (GU cancers) (<jats:italic>n<\/jats:italic>\u2009=\u200926, 24.5%), head and neck (H&amp;N) cancer (<jats:italic>n<\/jats:italic>\u2009=\u20094, 3.8%), and colorectal cancer (<jats:italic>n<\/jats:italic>\u2009=\u20091, 0.9%) were included in the study. The median (m) OS for the whole population was 14\u00a0months (CI 9.7\u201318.3), 9\u00a0months (CI 6.3\u201311.7) for patients with no IO-free period (<jats:italic>n<\/jats:italic>\u2009=\u200964, 62.1%), and 27.0\u00a0months (CI 20.6\u201333.4, <jats:italic>p<\/jats:italic>\u2009=\u20090.000001) for patients (<jats:italic>n<\/jats:italic>\u2009=\u200939) with IO-free period. The mIO-free survival was 10.0\u00a0months (CI 7.1\u201312.9) for the whole cohort, 8.0\u00a0months (CI 1.7\u201314.3) for lung cancer, 23.0\u00a0months (CI 2.6\u201343.4) for melanoma, and 14.0\u00a0months (CI 0.0\u201320.4) for GU cancer. From the IO-free cohort, 19 patients needed re-treatment during follow-up, of which 8 were re-challenged with anti-PD-(L)1 therapy. The clinical benefit rate of anti-PD-(L)1 re-challenge was 37.5%.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Our study shows that long IO-free periods can be achieved with limited duration of anti-PD-(L)1 therapy with excellent survival outcomes, and that anti-PD-(L)1 re-challenge is feasible in clinical practice.<\/jats:p>\n<\/jats:sec>","DOI":"10.1007\/s00432-020-03217-7","type":"journal-article","created":{"date-parts":[[2020,4,18]],"date-time":"2020-04-18T17:02:15Z","timestamp":1587229335000},"page":"2153-2160","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Treatment discontinuation and re-initiation of anti-PD-(L)1 agents in metastatic cancers"],"prefix":"10.1007","volume":"146","author":[{"given":"Antti","family":"Tikkanen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanna","family":"Iivanainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jussi P.","family":"Koivunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,18]]},"reference":[{"issue":"20","key":"3217_CR1","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, PACIFIC Investigators et al (2017) Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 377(20):1919\u20131929. https:\/\/doi.org\/10.1056\/NEJMoa1709937","journal-title":"N Engl J Med"},{"issue":"11","key":"3217_CR2","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","volume":"18","author":"AV Balar","year":"2017","unstructured":"Balar AV, Castellano D, O'Donnell PH, Grivas P, Vuky J, Powles T et al (2017) First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol 18(11):1483\u20131492. https:\/\/doi.org\/10.1016\/S1470-2045(17)30616-2","journal-title":"Lancet Oncol"},{"key":"3217_CR3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01464","author":"A Betof Warner","year":"2020","unstructured":"Betof Warner A, Palmer JS, Shoushtari AN, Goldman DA, Panageas KS, Hayes SA et al (2020) Long-term outcomes and responses to retreatment in patients with melanoma treated with PD-1 blockade. JCO. https:\/\/doi.org\/10.1200\/JCO.19.01464","journal-title":"JCO"},{"issue":"4","key":"3217_CR4","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/CMR.0000000000000341","volume":"27","author":"H Blasig","year":"2017","unstructured":"Blasig H, Bender C, Hassel JC, Eigentler TK, Sachse MM, Hiernickel J et al (2017) Reinduction of PD1-inhibitor therapy: first experience in eight patients with metastatic melanoma. Melanoma Res 27(4):321\u2013325. https:\/\/doi.org\/10.1097\/CMR.0000000000000341","journal-title":"Melanoma Res"},{"issue":"17","key":"3217_CR5","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373(17):1627\u20131639. https:\/\/doi.org\/10.1056\/NEJMoa1507643","journal-title":"N Engl J Med"},{"issue":"2","key":"3217_CR6","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373(2):123\u2013135. https:\/\/doi.org\/10.1056\/NEJMoa1504627","journal-title":"N Engl J Med"},{"issue":"19","key":"3217_CR7","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S et al (2018) Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med 378(19):1789\u20131801. https:\/\/doi.org\/10.1056\/NEJMoa1802357","journal-title":"N Engl J Med"},{"issue":"1","key":"3217_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/1759-7714.13241","volume":"11","author":"K Fujita","year":"2020","unstructured":"Fujita K, Yamamoto Y, Kanai O, Okamura M, Hashimoto M, Nakatani K et al (2020) Retreatment with anti-PD-1 antibody in non-small cell lung cancer patients previously treated with anti-PD-L1 antibody. Thorac Cancer 11(1):15\u201318. https:\/\/doi.org\/10.1111\/1759-7714.13241","journal-title":"Thorac Cancer"},{"issue":"22","key":"3217_CR9","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, KEYNOTE-189 Investigators et al (2018) Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378(22):2078\u20132092. https:\/\/doi.org\/10.1056\/NEJMoa1801005","journal-title":"N Engl J Med"},{"key":"3217_CR10","doi-asserted-by":"publisher","first-page":"e21009","DOI":"10.1200\/JCO.2019.37.15","volume":"37","author":"F Grude","year":"2019","unstructured":"Grude F, Travers M, Moiteaux B, Beneton N, Jacobzone C, Corre Y et al (2019) Nivolumab and Pembrolizumab in advanced cutaneous melanoma: Results from real-life data in patients from France\u2014evaluation of use, current practices and medico economic approach. J Clin Oncol 37:e21009. https:\/\/doi.org\/10.1200\/JCO.2019.37.15","journal-title":"J Clin Oncol"},{"issue":"21","key":"3217_CR11","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","volume":"381","author":"MD Hellmann","year":"2019","unstructured":"Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E et al (2019) Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med 381(21):2020\u20132031. https:\/\/doi.org\/10.1056\/NEJMoa1910231","journal-title":"N Engl J Med"},{"issue":"10027","key":"3217_CR12","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387(10027):1540\u20131550. https:\/\/doi.org\/10.1016\/S0140-6736(15)01281-7","journal-title":"Lancet"},{"issue":"23","key":"3217_CR13","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","volume":"379","author":"L Horn","year":"2018","unstructured":"Horn L, Mansfield AS, Szczesna A, Havel L, Krzakowski M, Hochmair MJ, IMpower133 Study Group et al (2018) First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 379(23):2220\u20132229. https:\/\/doi.org\/10.1056\/NEJMoa1809064","journal-title":"N Engl J Med"},{"issue":"3","key":"3217_CR14","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1159\/000493193","volume":"96","author":"S Iivanainen","year":"2019","unstructured":"Iivanainen S, Koivunen JP (2019) Early PD-1 therapy discontinuation in responding metastatic cancer patients. Oncology 96(3):125\u2013131. https:\/\/doi.org\/10.1159\/000493193","journal-title":"Oncology"},{"issue":"7","key":"3217_CR15","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1093\/annonc\/mdz110","volume":"30","author":"YJL Jansen","year":"2019","unstructured":"Jansen YJL, Rozeman EA, Mason R, Goldinger SM, Geukes Foppen MH, Hoejberg L et al (2019) Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. Ann Oncol 30(7):1154\u20131161. https:\/\/doi.org\/10.1093\/annonc\/mdz110","journal-title":"Ann Oncol"},{"issue":"15","key":"3217_CR16","doi-asserted-by":"publisher","first-page":"9503","DOI":"10.1200\/JCO.2018.36.15suppl.9503","volume":"36","author":"GV Long","year":"2018","unstructured":"Long GV, Schachter J, Ribas A, Arance AM, Grob J, Mortier L et al (2018) 4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006. JCO 36(15):9503. https:\/\/doi.org\/10.1200\/JCO.2018.36.15suppl.9503","journal-title":"JCO"},{"issue":"19","key":"3217_CR17","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, CheckMate 025 Investigators et al (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373(19):1803\u20131813. https:\/\/doi.org\/10.1056\/NEJMoa1510665","journal-title":"N Engl J Med"},{"issue":"14","key":"3217_CR18","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Tannir NM, McDermott DF, Aren Frontera O, Melichar B, Choueiri TK, CheckMate 214 Investigators et al (2018) Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 378(14):1277\u20131290. https:\/\/doi.org\/10.1056\/NEJMoa1712126","journal-title":"N Engl J Med"},{"issue":"64","key":"3217_CR19","doi-asserted-by":"publisher","first-page":"32298","DOI":"10.18632\/oncotarget.25949","volume":"9","author":"M Niki","year":"2018","unstructured":"Niki M, Nakaya A, Kurata T, Yoshioka H, Kaneda T, Kibata K et al (2018) Immune checkpoint inhibitor re-challenge in patients with advanced non-small cell lung cancer. Oncotarget 9(64):32298\u201332304. https:\/\/doi.org\/10.18632\/oncotarget.25949","journal-title":"Oncotarget"},{"issue":"19","key":"3217_CR20","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, KEYNOTE-024 Investigators et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375(19):1823\u20131833. https:\/\/doi.org\/10.1056\/NEJMoa1606774","journal-title":"N Engl J Med"},{"issue":"12","key":"3217_CR21","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D et al, KEYNOTE-426 Investigators (2019) Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380(12):1116\u20131127. https:\/\/doi.org\/10.1056\/NEJMoa1816714","journal-title":"N Engl J Med"},{"issue":"10066","key":"3217_CR22","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","volume":"389","author":"A Rittmeyer","year":"2017","unstructured":"Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J et al, OAK Study Group (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389(10066):255\u2013265. https:\/\/doi.org\/10.1016\/S0140-6736(16)32517-X","journal-title":"Lancet"},{"issue":"4","key":"3217_CR23","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L et al (2015a) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372(4):320\u2013330. https:\/\/doi.org\/10.1056\/NEJMoa1412082","journal-title":"N Engl J Med"},{"issue":"26","key":"3217_CR24","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, KEYNOTE-006 investigators et al (2015b) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372(26):2521\u20132532. https:\/\/doi.org\/10.1056\/NEJMoa1503093","journal-title":"N Engl J Med"},{"issue":"17","key":"3217_CR25","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1200\/JCO.2017.75.6270","volume":"36","author":"C Robert","year":"2018","unstructured":"Robert C, Ribas A, Hamid O, Daud A, Wolchok JD, Joshua AM et al (2018) Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. J Clin Oncol 36(17):1668\u20131674. https:\/\/doi.org\/10.1200\/JCO.2017.75.6270","journal-title":"J Clin Oncol"},{"key":"3217_CR26","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx380.002","author":"DR Spigel","year":"2017","unstructured":"Spigel DR, McLeod M, Hussein MA, Waterhouse DM, Einhorn L, Horn L et al (1297ORandomized) 1297ORandomized results of fixed-duration (1-yr) vs continuous nivolumab in patients (pts) with advanced non-small cell lung cancer (NSCLC). Ann Oncol. https:\/\/doi.org\/10.1093\/annonc\/mdx380.002","journal-title":"Ann Oncol"},{"issue":"10","key":"3217_CR27","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","volume":"32","author":"SL Topalian","year":"2014","unstructured":"Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH et al (2014) Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32(10):1020\u20131030. https:\/\/doi.org\/10.1200\/JCO.2013.53.0105","journal-title":"J Clin Oncol"},{"issue":"8","key":"3217_CR28","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1093\/jjco\/hyz066","volume":"49","author":"H Watanabe","year":"2019","unstructured":"Watanabe H, Kubo T, Ninomiya K, Kudo K, Minami D, Murakami E et al (2019) The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer. Jpn J Clin Oncol 49(8):762\u2013765. https:\/\/doi.org\/10.1093\/jjco\/hyz066","journal-title":"Jpn J Clin Oncol"},{"issue":"19","key":"3217_CR29","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, CheckMate 238 Collaborators et al (2017) Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med 377(19):1824\u20131835. https:\/\/doi.org\/10.1056\/NEJMoa1709030","journal-title":"N Engl J Med"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-020-03217-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-020-03217-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-020-03217-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T23:35:04Z","timestamp":1618702504000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-020-03217-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,18]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["3217"],"URL":"https:\/\/doi.org\/10.1007\/s00432-020-03217-7","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,18]]},"assertion":[{"value":"16 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have declared no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"According to national legislation, informed consent is not needed due to the retrospective and non-interventional nature of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and Informed consent"}}]}}